Delivery Order SPE2DR25D2206-SPE2DR26F9EJ3
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 10, 2025, for the supply of Durolane 60 mg/3 mL syringes with a ceiling value of $10,514.15. This non-competitive, firm fixed-price delivery order is set to be completed by December 11, 2025, and will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Durolane 60 mg/3 mL syringes with a ceiling value of $5.4K. This is a firm fixed price delivery order with an ultimate completion date of July 30, 2025, and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award was competitively awarded with no set-aside designation. This delivery order is issued under AmerisourceBergen...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,565.96 to AmerisourceBergen Drug Corp for the supply of Durolane 60 mg/3 mL syringes on December 5, 2025, with a completion date of December 8, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed price pricing and represents a single delivery order under AmerisourceBergen's larger indefinite delivery contract with DLA. The product will be delivered to the company's corporate headquarters location in...
- The Defense Logistics Agency awarded a delivery order valued at $5,495.41 to AmerisourceBergen Drug Corp for the supply of Durolane 60 mg/3 mL syringes on December 11, 2025, with completion targeted for December 12, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's significantly...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Durolane 60 mg/3 mL syringes valued at $7,568.71, with an ultimate completion date of November 13, 2025. This contract was awarded on a firm fixed-price basis without set-aside designation, indicating competitive procurement. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 24, 2025, for the supply of Durolane 60 mg/3 ml syringes with a contract value of $2,290.11 and an ultimate completion date of November 25, 2025. This non-competitive delivery order utilizes firm fixed pricing and is executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $1 billion prime vendor agreement designated SPE2DX and running through...
- The Defense Logistics Agency awarded a $18,044.80 delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Durolane 60 mg/3 ml syringes. This firm fixed-price contract, with a completion date of September 11, 2025, represents a non-competitive delivery order under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The product will be performed at the vendor's location in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency awarded a $1,679.80 delivery order to AmerisourceBergen Drug Corp on December 3, 2025, for the supply of Durolane 60 mg/3 ml syringes. This competitively awarded, firm fixed-price delivery order is expected to be completed by December 4, 2025, with fulfillment occurring at the vendor's facility in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, a...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $1,275.20 firm fixed-price delivery order for Durolane 60 mg/3 ml syringes on June 5, 2025, with an ultimate completion date of June 6, 2025. This non-competitive, non-set-aside award is being performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. The delivery order represents a child contract action under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a...
- The Defense Logistics Agency awarded a $6,257.14 delivery order to AmerisourceBergen Drug Corp for Durolane 60 mg/3 mL syringes on December 16, 2025, with a completion date of December 17, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply vehicle. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania, where the...
- SPE2DR25D2206Indefinite Delivery Contract
- SPE2DR25D2206-SPE2DR26F9EJ3Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 4, 2025, for the supply of Durolane 60 mg/3 ml syringes with a ceiling value of $12.7K under firm fixed pricing. This is a non-set-aside, competitively awarded contract with an ultimate completion date of December 5, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999.9M and extends through December 2026, serving as a comprehensive global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical vendor for federal medical procurement, leverages this expansive IDC to supply a diverse portfolio of pharmaceutical products and medical supplies to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's track record with DLA demonstrates its capability to deliver medications and medical commodities across multiple therapeutic domains through open competition. Durolane, a hyaluronic acid injection used for osteoarthritis treatment, represents one component of the broader pharmaceutical support the contractor provides to support military healthcare operations worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.7k | 12/3/25 |